News

Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...
StockStory.org on MSN3d
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q2 CY2025, but sales were flat year on year at $12.27 ...
Bristol-Myers Squibb shares snapped six-session losing streak
Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors
This was the stock's fifth consecutive day of losses.
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...
Fierce Pharma3d
Bristol Myers touts commercial execution, reckons with recent clinical setbacks
Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...
BioPharma Dive5d
Bain leads $300M investment in startup built on Bristol Myers immune drugs
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...